Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Lexeo Therapeutics (LXEO) Research & Development (2022 - 2026)

Lexeo Therapeutics' Research & Development history spans 2 years, with the latest figure at -$44.9 million for Q4 2023.

  • On a quarterly basis, Research & Development fell 494.48% to -$44.9 million in Q4 2023 year-over-year; TTM through Sep 2023 was $56.3 million, a N/A change, with the full-year FY2025 number at $63.8 million, down 13.89% from a year prior.
  • Research & Development hit -$44.9 million in Q4 2023 for Lexeo Therapeutics, down from $17.2 million in the prior quarter.
  • Over the last five years, Research & Development for LXEO hit a ceiling of $17.2 million in Q3 2023 and a floor of -$44.9 million in Q4 2023.